Home » Ambry Genetics Certified as Agilent Provider

Ambry Genetics Certified as Agilent Provider

Sep 01, 2009

NEW YORK (GenomeWeb News) – Genomics services company Ambry Genetics said Tuesday that it has been certified to provide services at its California lab using Agilent Technologies' microarray platforms.

Ambry Genetics said it passed an assessment program to provide comparative genomic hybridization services to detect genomic copy number variations in specific genomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Mar 12, 2014

Denying Injunction against Ambry BRCA Testing, Utah Judge Unconvinced of Myriad's Legal Success

Premium
Mar 11, 2014

Utah Court Denies Myriad, BRCA Patent Holders' Preliminary Injunction Request Against Ambry

Jun 02, 2014

Multiple Institutions, Labs Collaborating on Registry to Study Rare Hereditary Cancer Genes

Jun 25, 2014

Columbia Geneticists Find Routine Exome Sequencing Successful but Still Not First-line Choice

Premium
Sep 24, 2014

Ambry, Academic Groups Partner to Create Hereditary Cancer Registry

Jun 25, 2014

Ambry, Kapa Bio Reach Deal on Exome Sequencing Assays

The Scan

This Week in PNAS

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

Leaving It All Over Town

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

Balance of Research and Privacy

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

What We'd Do With the Money

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

What's Popular?

In Microarrays & Multiplexing

  1. NanoString's Q4 Revenues Jump 54 Percent

  2. Agena Bioscience Launches Smaller Format MassArray as Part of New Clinical Direction

    Premium

  3. Signal Genetics Closes $9M Public Offering of Stock

  4. GenMark Q4 Revenues Grow 51 Percent

  5. CombiMatrix Posts 27 Percent Q4 Revenue Growth

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.